AIDS immune cell therapy apparatus

Abstract

The invention discloses an AIDS immune cell therapy apparatus, which is applicable to the medicine field. The AIDS immune cell therapy apparatus is characterized in that blood and plasma separators, by which plasma, individual blood cells and multinuclear giant cells which are formed due to HIV boarding, are prepared; by virtue of an exogenous gene transfection technique, a CD4+T cell line, which can bond HIV, is prepared, the CD4+T cell line undergoes amplification and the CD4+T cell line is covered by virtue of a high-biocompatibility material, so that a purifier is prepared; and then, agarose, which is subjected to a gradient concentration, is added, and the CD4+T cell line in the purifier is immobilized so as to take an effect on adsorbing the HIV; the purifier, together with the separators, functions as key parts of an extracorporeal circulation device; when blood passes through the blood separator, the multinuclear giant cells which contain the HIV are filtered out, subsequently, when the plasma, which is separated by virtue of the plasma separator, passes through the purifier, HIV in the plasma is adsorbed and scavenged by virtue of a purifying agent, the purified plasma joins with the individual blood cells which are separated by virtue of the plasma separator, and then the plasma is returned back, so that the purpose of scavenging the HIVs inside and outside the blood cells by virtue of a detoxifying and purifying therapy is achieved.

Description

technical field [0001] The invention relates to the preparation and application of an AIDS immune cell therapy instrument in the medical field, which is mainly used for removing HIV inside and outside blood cells of AIDS patients so as to achieve the purpose of treatment. Background technique [0002] AIDS is an infectious disease caused by human immunodeficiency virus (Human Immunodeficiency Virus, HIV). So far, 208 countries and regions in the world have been seriously threatened by AIDS. About 40 million people have been infected with AIDS, and the death toll has exceeded 20 million. About 6,000 people become AIDS-infected people every day, and more than 300 people die every day. on AIDS. HIV-infected people in China are in a period of rapid growth, and the number has far exceeded 1 million at present. AIDS has become another major infectious disease facing mankind after tumors, cardiovascular and cerebrovascular diseases, tuberculosis, and diabetes, and has become a se...

AI Technical Summary

Problems solved by technology

However, the antibody cannot contact the virus remaining in the mononuclear macrophage, and the HIV envelope protein is prone to antigenic variation, and the original antibody loses its effect, so that the neutralizing antibody cannot play its due role

During the latent infection stage, the HIV provirus is integrated into the host cell genome, so HIV will not be recognized by the immune system, so it cannot be eliminated by autoimmunity alone

Another very important reason should be that, based on the mechanism of antibody killing and clearing antigens, it is speculated that after the immune antibody binds to the antigen, if it wants to produce an immune effect, it must either activate the complement and mediate the ADCC effect to dissolve the cellular antigen, but HIV It is not a cellular antigen; either it attracts phagocytes to phagocytize and clear the antigen through chemotaxis, but HIV is protected and proliferates in the phagocytes instead; or the antibody binds to the antigen to neutralize it, making it lose its infectivity, but HIV antigens have many structures Mutations, often making it difficult for antibodies to recognize

[0006] Judging from the current AIDS treatment methods that have been used clinically, the effect is not so ideal: (1) HIV reverse transcriptase inhibitors: can only prevent the infection of susceptible cells that have not been infected with HIV, and have no therapeutic effect on infected cells, and are toxic There are many side effects, including mitochondrial toxicity, myelosuppression, erythrocytic anemia, neutropenia and thrombocytopenia, pancreatitis, and the generation of cross-drug resistance. Drug-resistant variants, resulting in decreased clinical efficacy or failure

(2) HIV protease inhibitors: prone to drug-induced liver injury, lipid metabolism disorders and other side effects and drug resistance

(4) Inhibiting HIV virus entry inhibitors: including blocking the binding of gp120 to CD4, blocking the binding of HIV to coreceptors, acting on gp41 membrane subunits, and acting on CC chemokine receptor 5 (CCR5) on the surface of T lymphocytes to block HIV from entering host cells, but has side effects on the liver and heart

(6) HIV vaccine treatment: Due to the particularity of HIV, such as innate immunity is not enough to resist HIV and its targeted destruction of the immune system, and the virus mutates rapidly, so far no truly safe and effective vaccine has been developed

(7) Gene therapy: HIV gene therapy research has never stopped, including antisense technology, RNA decoy, RNA interference, intracellular antibodies, dominant negative mutants, suicide genes, etc., but gene therapy that has entered phase II clinical trials hardly

[0009] In short, various drugs and biological products cannot effectively kill HIV in the body, and they are expensive and have severe side effects. So far, there is no effective method for the treatment of AIDS, which has become a worldwide problem that cannot be overcome for a long time.

Images